Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$23.65 – $28.12
53% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $94.17B | $89.23B | $74.98B | $76.03B | $72.98B | $72.04B | $94.03B | $77.35B |
| Cost of revenue | $40.37B | $38.75B | $34.07B | $34.46B | $33.43B | $33.51B | $35.50B | $37.87B |
| Gross profit | $53.80B | $50.48B | $40.91B | $41.58B | $39.56B | $38.54B | $58.53B | $39.49B |
| Gross margin | 57.1% | 56.6% | 54.6% | 54.7% | 54.2% | 53.5% | 62.2% | 51.0% |
| R&D | $10.26B | $6.42B | $6.74B | $8.42B | $15.79B | $12.54B | $18.73B | $20.71B |
| Operating income | $24.59B | $26.51B | $17.79B | $17.06B | $8.00B | $9.51B | $21.03B | −$904.7M |
| EBITDA | $27.19B | $29.37B | $20.99B | $16.38B | $9.40B | $12.57B | $22.02B | $2.44B |
| Net income | $17.77B | $19.37B | $13.40B | $9.55B | $5.44B | $8.03B | $13.95B | $2.16B |
| Net margin | 18.9% | 21.7% | 17.9% | 12.6% | 7.5% | 11.1% | 14.8% | 2.8% |
| EPS (diluted) | 445.78 | 494.89 | 347.37 | 251.44 | 144.79 | 212.66 | 365.42 | 57.52 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $79.2B | $93.59 | $84.03–$109.56 | 1 |
| 2028 | $82.5B | $124.62 | $111.89–$145.88 | 1 |
| 2029 | $84.2B | $107.33 | $96.36–$125.64 | 1 |
| 2030 | $96.7B | $140.71 | $126.33–$164.72 | 1 |
Forward consensus · source: Financial Modeling Prep
KAKEN PHARM CO
No one on the platform currently holds KKPCF.
No tracked institution reports a position in KKPCF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2027-03-31 | $95.0000 | |
| 2026-09-30 | $95.0000 | |
| 2026-03-31 | $95.0000 | 2026-06-29 |
| 2025-09-30 | $95.0000 | 2025-11-28 |
| 2025-03-31 | $75.0000 | 2025-06-30 |
| 2024-09-30 | $75.0000 | 2024-11-29 |
| 2024-09-30 | $40.0000 | 2024-11-29 |
| 2024-03-28 | $75.0000 | 2024-06-28 |
| 2023-09-29 | $75.0000 | 2023-11-30 |
No one on the platform has traded KKPCF yet.
| $521M |
| — |
| CSWYFChina Shineway Pharmaceutical Group Limited | $1.00 | +0.00% | $758M | — |
| DGWPFDrägerwerk AG & Co. KGaA | $83.00 | +0.00% | $1.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.1× earnings vs its 0.1× historical median P/E.
Fair value ≈ $47.18 · price $26.00 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.